2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Neuroblastoma
44
Ganglioneuroblastoma
5
Medulloblastoma
4
Lung Neoplasms
4
Leukemia, Myelomonocytic, Juvenile
4
Glioblastoma
4
Brain Neoplasms
4
Uterine Cervical Neoplasms
3
Small Cell Lung Carcinoma
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Leukemia, Myeloid, Acute
3
Leukemia
3
Kidney Neoplasms
3
Head and Neck Neoplasms
3
Gliosarcoma
3
Glioma
3
Central Nervous System Neoplasms
3
Carcinoma, Renal Cell
3
Carcinoma, Non-Small-Cell Lung
3
Astrocytoma
3
Squamous Cell Carcinoma of Head and Neck
2
Rhabdoid Tumor
2
Recurrence
2
Prostatic Neoplasms
2
Pinealoma
2
Oligodendroglioma
2
Neoplasms
2
Myelodysplastic Syndromes
2
Mycosis Fungoides
2
Lymphoma, Large B-Cell, Diffuse
2
Interventions
Amifostine
19
Cisplatin
15
Radiotherapy
13
Etoposide
10
Cyclophosphamide
9
Carboplatin
8
Paclitaxel
7
Filgrastim
7
Drug Therapy
5
Cytarabine
5
apatinib
4
Methotrexate
4
sodium thiosulfate
3
Methylprednisolone
3
Gemcitabine
3
Docetaxel
3
sargramostim
2
pegfilgrastim
2
glucarpidase
2
etoposide phosphate
2
denileukin diftitox
2
camrelizumab
2
Voriconazole
2
Vincristine
2
Social Determinants of Health
2
Pyridoxine
2
Peripheral Blood Stem Cell Transplantation
2
Nivolumab
2
Mitoxantrone
2
Melphalan
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Drug-Related Side Effects and Adverse Reactions
×
Isotretinoin
×
Clear all
NCT00002586
2020-05-15
13-Cis
University of Colorado, Denver
Phase 2
Completed
96 enrolled